NEW HAVEN, Conn., March 27 /PRNewswire/ -- Ikonisys, Inc., a leading developer of cell-based diagnostic products, today announced that the Ikoniscope(TM)/IkoniLAN(TM) Platform obtained a CE Mark.
The Ikoniscope(TM)/IkoniLAN(TM) Platform allows for seamless robotic microscopy with applications in the fields of genetic testing, oncology, and fertility. The use of the Ikonisys technology opens up exciting new opportunities including a test that will offer prenatal diagnosis of major chromosomal abnormalities using fetal cells circulating in the maternal blood.
“This is a major milestone for Ikonisys. It will give us the opportunity to market our applications in one of the largest markets, the European market. We are proud that the Ikonisys team developed a robotic platform that changes the way genetic testing is done. We are confident that our current product along with the applications that will follow will have a major impact to our laboratory customers and the health of patients,” said Dr. Petros Tsipouras, Chairman and CEO of Ikonisys.
Ikonisys is a privately held medical technology company that is developing products for diagnosing diseases early using chromosome FISH dot counting and rare-cell identification and analysis. Based on its proprietary technology, Ikonisys aims to expand a novel field of medical diagnostic analysis, namely cell-based diagnostics. Additional information about Ikonisys can be found at http://www.ikonisys.com.
Contact: Petros Tsipouras, MD Chairman and CEO Ikonisys, Inc. Phone Number: 203-776-0791 Email: tsipouras@ikonisys.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Ikonisys, Inc.
CONTACT: Petros Tsipouras, MD, Chairman and CEO of Ikonisys, Inc.,+1-203-776-0791, or tsipouras@ikonisys.com
Web site: http://www.ikonisys.com/
